Sucralfate

A to Z Drug Facts

Sucralfate

 Actions
 Indications
 Contraindications
 Route/Dosage
 Interactions
 Lab Test Interferences
 Adverse Reactions
 Precautions
Patient Care Considerations
 Administration/Storage
 Assessment/Interventions
 Patient/Family Education


(sue-KRAL-fate)
Carafate
Suspension: 1 g/10 mL
Tablets: 1 g
Sulcrate
Tablets: 1 g
Class: Gastrointestinal

 Actions Adheres to ulcer in acidic gastric juice, forming protective layer that serves as barrier against acid, bile salts, and enzymes present in stomach and duodenum.

 Indications Short-term treatment of duodenal ulcer; maintenance therapy of duodenal ulcer.

Treatment of gastric ulcers; reflux and peptic esophagitis; treatment of NSAID- or aspirin-induced GI symptoms and mucosal damage; prevention of stress ulcers and GI bleeding in critically ill patients; treatment of oral and esophageal ulcers caused by radiation, chemotherapy, and sclerotherapy; treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.

 Contraindications Standard considerations.

 Route/Dosage

Active Duodenal Ulcer: ADULTS: PO 1 g qid on empty stomach (1 hr before meals and at bedtime) for 4 to 8 wk. Maintenance (tablets only): 1 g bid.

 Interactions

Aluminum-containing antacids: May increase total body burden of aluminum. Cimetidine, ciprofloxacin (and other quinolone antibiotics), diclofenac, digoxin, hydantoins (eg, phenytoin), ketoconazole, pencillamine, ranitidine, tetracycline, theophylline: Oral absorption and pharmacologic action of these agents may be reduced if given with sucralfate. Administer 2 hr apart from sucralfate.

 Lab Test Interferences None well documented.

 Adverse Reactions

CNS: Dizziness; insomnia; vertigo; headache. DERMATOLOGIC: Rash; pruritus. GI: Constipation; diarrhea; nausea; vomiting; dry mouth; indigestion; flatulence. OTHER: Back pain.

 Precautions

Pregnancy: Category B. Lactation: Undetermined. Children: Safety and efficacy not established. Chronic renal failure/dialysis: Small amounts of aluminum may be absorbed from sucralfate, and concomitant use of other aluminum-containing products may increase total body burden of aluminum. Aluminum is not removed by dialysis and excretion through kidneys is impaired in patients with chronic renal failure. Aluminum accumulation and toxicity (eg, aluminum osteodystrophy, osteomalacia, encephalopathy) have occurred.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts